HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The sensitivity and specificity of the routine kidney biopsy immunofluorescence panel are inferior to diagnosing renal immunoglobulin-derived amyloidosis by mass spectrometry.

Abstract
Immunoglobulin light chain amyloidosis is the most frequent type of renal amyloidosis in the United States, accounting for 81% of cases. Accurate typing is crucial for early diagnosis and treatment of immunoglobulin-derived amyloidosis and to avoid treating other amyloidoses with potentially toxic chemotherapy. Immunofluorescence is the first step to type renal immunoglobulin-derived amyloidosis but the performance characteristics of this method are largely unknown. Here, we establish the sensitivity and specificity of immunofluorescence for diagnosing immunoglobulin-derived amyloidosis in patients whose amyloid typing was performed by the current gold standard of laser microdissection/mass spectrometry. Renal biopsy pathology reports originating from several institutions with a diagnosis of amyloidosis and which had amyloid typing by laser microdissection/mass spectrometry performed at our center were reviewed. Reported immunofluorescence staining for kappa or lambda of 2+ or more, with weak or no staining for the other light chain was considered positive for light chain amyloidosis by immunofluorescence. Based on microdissection/mass spectrometry results, of the 170 cases reviewed, 104 cases were typed as immunoglobulin-derived amyloidosis and 66 were typed as non-immunoglobulin-derived amyloidosis. Immunofluorescence sensitivity for diagnosing immunoglobulin-derived amyloidosis was 84.6%. The remaining 16 cases could not be diagnosed by immunofluorescence due to reported weak staining for all antigens or reported lack of preferential staining for one antigen. Immunofluorescence specificity was 92.4%. Five cases, all amyloid A amyloidosis, were misdiagnosed as immunoglobulin-derived amyloidosis by immunofluorescence. Immunofluorescence failed to accurately differentiate immunoglobulin-derived from non-immunoglobulin-derived amyloidosis in 12.3% of cases of renal amyloidosis. Relying on immunofluorescence alone for determining immunoglobulin-derived vs. non-immunoglobulin-derived amyloidosis may lead to misdiagnosis. Thus, immunofluorescence has inferior sensitivity and specificity compared with laser microdissection/mass spectrometry in the typing of immunoglobulin-derived amyloidosis.
AuthorsMaria L Gonzalez Suarez, Pingchuan Zhang, Samih H Nasr, Insara Jaffer Sathick, Wonngarm Kittanamongkolchai, Paul J Kurtin, Mariam P Alexander, Lynn D Cornell, Mary E Fidler, Joseph P Grande, Loren P Herrera Hernandez, Samar M Said, Sanjeev Sethi, Angela Dispenzieri, Morie A Gertz, Nelson Leung
JournalKidney international (Kidney Int) Vol. 96 Issue 4 Pg. 1005-1009 (10 2019) ISSN: 1523-1755 [Electronic] United States
PMID31447055 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2019 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Biopsy
  • Female
  • Fluorescent Antibody Technique
  • Humans
  • Immunoglobulin Light-chain Amyloidosis (diagnosis, pathology)
  • Kidney (pathology)
  • Laser Capture Microdissection (statistics & numerical data)
  • Male
  • Mass Spectrometry (statistics & numerical data)
  • Middle Aged
  • Nephrotic Syndrome (diagnosis, pathology)
  • Retrospective Studies
  • Sensitivity and Specificity
  • United States

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: